Table 2.

Summary of reported metabolic drug interactions during coadministration of ticlopidine^*.

Drug affected	Type of study	Observed effects** [references]	Metabolism of affected drug***
Phenytoin	Open label	↑Km and serum levels [5]	CYP2C9, 2C19
	Case report and in vitro	↑Serum levels and toxicity [4]
	Case report	↑Serum levels and toxicity [8]
	Case report	↑Serum levels and toxicity [10]
	Case report	↑Serum levels and toxicity [9]
	Case report	↑Serum levels and toxicity [6]
	Case report	↑Serum levels and toxicity [7]
Carbamazepine	Case report	↑Serum levels and toxicity [13]	CYP3A, 2C8
Antipyrine	Placebo-controlled	↑t½ (27%) and AUC (14%) [15]	CYP1A2, 2C9, 3A
Theophylline	Placebo-controlled	↑ t½ (42) and ↓Cl (37%) [12]	CYP1A2, 2E1, 3A
R-Warfarin	Open study	↑Plasma levels (26%) [14]	CYP1A2, 3A, 2C19
S-Warfarin	Open study	No effect [14]	CYP2C9
Omeprazole	Placebo-controlled	↓5-hydroxylation [11]	CYP2C19
Omeprazole	Placebo-controlled	No effect on sulphone formation [11]	CYP3A
Cyclosprin A	Placebo-controlled	No effect [43]	CYP3A

^*Onset of interaction, 5 days to 6 weeks after ticlopidine administration

^**Phenytoin toxicity reported: ataxia, drowsiness, vertigo, gaitdisturbances and leg weakness

^***reference [1].